ClinicalTrials.gg
CompletedNCT05657938Updated Aug 14, 2023

Evaluation of Home Based Assessments on Participants With DMD

An observational study in Duchenne Muscular Dystrophy, sponsored by Solid Biosciences Inc.. Completed at 1 site in United States. Open to male participants aged 4 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Solid Biosciences Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
17
Ages
4 Years to 12 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
49th of 55
17 · median 75
Started
2022
with 14 others
Observational
55 of 233
16 open now
Registered
186th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 49th largest by enrollment of the 55 observational ones that give a count, is one of 15 that started in 2022, is one of 55 observational ones, and was the 186th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 12 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the feasibility, wearability and participant satisfaction of novel outcome assessment tools in DMD patients which are performed in the home environment.

Read the detailed description

This is a low interventional feasibility study to evaluate the use of:

  1. An FDA 510(k) cleared Class II wearable medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting, and;
  2. The Duchenne Video Assessment (DVA) tool to evaluate the quality of movement in patients with Duchenne Muscular Dystrophy (DMD)

This study will provide data on suitability of these tools in future clinical trials.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • duchenne
  • muscular dystrophy
  • DMD
04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Approximately twenty ambulatory males aged 4 to \<13 years with DMD will be recruited. Of these, approximately 10 participants will be considered Early Ambulatory and 10 will be considered Late Ambulatory. Early ambulatory is defined as able to get off the floor without assistance or use of furniture.

Approximately twenty healthy, age-matched controls will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For DMD patients:

  1. Parent/guardian or participant is able to give and/or assent as required by local regulations, and all are willing and able to comply with the protocol.
  2. Participant is assigned male sex at birth and is age 4 to \<13 years at time of consent.
  3. Participant has a confirmed diagnosis of DMD based on genetic testing and/or clinical records consistent with the diagnosis.
  4. Participant has been on a stable dose for 3 months prior to participation.
  5. Participant is ambulatory as defined by the ability to walk down a hallway at home without assistance or support.

For healthy age-matched controls:

  1. Parent/guardian or participant is able to give informed consent and/or assent as required by local regulations, and all are willing and able to comply with the protocol.
  2. Participant is assigned male sex at birth and age 4 to \<13 years at time of consent.

Exclusion criteria

Exclusion Criteria:

For DMD Patients:

  1. Participant is/was enrolled in any interventional study for DMD in the past 3 months or has ever been enrolled in a gene therapy study.
  2. Participant is on any approved therapy for DMD except for .
  3. Participant is currently or was previously treated with exon-skipping antisense oligonucleotides such as eteplirsen, golodirsen, casimersen, and viltolarsen.
  4. Participant has any prior or ongoing medical condition, medical history, or physical finding that could affect the participant's ability to perform the study assessments.
  5. Participant has had major surgery within 3 months prior to recruitment or planned orthopedic surgery for any time during this study which would interfere with the ability to perform assessments.
  6. Participant has a history of allergic response to silicones or adhesives.
  7. Participant has an active implanted device (e.g., pacemaker). Implanted devices relying on an electrical power source to function are considered active devices.

For healthy age-matched controls:

  1. Participant has a known musculoskeletal disease or had a musculoskeletal injury in the past 3 months.
  2. Participant has other illness that precludes functional testing.
  3. Participant is enrolled in any interventional study.
  4. Participant has or has had any prior or ongoing medical condition, medical history, or physical finding that could affect the participant's ability to perform the study assessments.
  5. Participant has had major surgery within 3 months prior to recruitment or planned orthopedic surgery for any time during this study which would interfere with the ability to perform study assessments.
  6. Participant has a history of allergic response to silicones or adhesives.
  7. Participant has an active implanted device (e.g., pacemaker). Implanted devices relying on an electrical power source to function are considered active devices.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
17 participants (actual)
Patient registry
No

Groups and cohorts

  • DMD Patients

    Ambulatory males aged 4 to \<13 years with Duchenne Muscular Dystrophy

    Device: Wearable Device · Other: Duchenne Video Assessment (DVA)

  • Age Matched Controls

    Normal male age-matched controls

    Device: Wearable Device · Other: Duchenne Video Assessment (DVA)

Interventions

  • DeviceWearable Device

    The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.

  • OtherDuchenne Video Assessment (DVA)

    The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.

06

What researchers measure

Primary outcomes

  1. Wearable sensor device compliance

    The wearable sensor device is composed of three small sticker-based sensors that are worn on the chest, thigh and ankle to record activity. Participants will wear the sensors during specified periods over the study duration and compliance will be assessed based on recorded activity.

    Time frame: 30 days

  2. Accuracy of functional evaluation using the Duchenne Video Assessment (DVA) tool in an at-home setting

    The DVA is a digital tool designed to remotely evaluate functional capacity in a natural environment. Participants will complete a set of movement tasks at specified timepoints during the study that will be captured on video and scored by remote evaluators. DVA scoring will be compared with anticipated levels of functional capacity to assess accuracy.

    Time frame: 30 days

  3. Preference for use of the wearable sensor device and DVA tool as assessed by interview

    Participants will be asked to complete an exit interview at the conclusion of the study to assess user preference.

    Time frame: Day 24-30

07

Study locations

1 site
  • Solid Biosciences
    Charlestown, Massachusetts 02129, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2023, 5 months.

Of 63 observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 120. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Dec 20, 2022
StartActual
Oct 13, 2022
Primary completionActual
Apr 4, 2023
CompletionActual
Apr 4, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05657938
Lead sponsor
Solid Biosciences Inc.
Responsible party
Sponsor
First posted
Dec 20, 2022
Start date
Oct 13, 2022
Primary completion
Apr 4, 2023
Completion
Apr 4, 2023
Last update
Aug 14, 2023

Study contacts

Carl A Morris, PhD
study director · Solid Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion